Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD7 CAR-T in CD7+ Acute Leukemia
NCT04938115Phase 1Completed
- Sponsor
- Senlang Bio
- Start
- May 2021
- Primary completion
- May 2023
- Modality
- Autologous CAR-T
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of PA3-17 in acute myeloid leukemia (AML) and mixed phenotype acute leukemia (MPAL), sponsored by Senlang Bio. Primary endpoints: Incidence and severity of adverse events at 1 month and Remission Rate at 3 months. Started May 2021; status: completed.
02
Drugs
PA3-17
03
Conditions
acute myeloid leukemia (AML)mixed phenotype acute leukemia (MPAL)
Beyond the preview
Go deeper on NCT04938115.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04938115.